Illumine Investment Management LLC Makes New $633,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Illumine Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 17,049 shares of the company’s stock, valued at approximately $633,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. increased its position in Amphastar Pharmaceuticals by 10.9% in the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock worth $10,605,000 after buying an additional 21,530 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth about $11,070,000. Pacer Advisors Inc. lifted its position in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the last quarter. Wellington Management Group LLP acquired a new position in Amphastar Pharmaceuticals during the 3rd quarter valued at about $957,000. Finally, XTX Topco Ltd bought a new position in Amphastar Pharmaceuticals in the 3rd quarter worth about $674,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Up 0.9 %

AMPH stock opened at $31.49 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market capitalization of $1.51 billion, a P/E ratio of 10.50, a P/E/G ratio of 2.19 and a beta of 0.81. Amphastar Pharmaceuticals, Inc. has a 52-week low of $30.34 and a 52-week high of $55.95. The company’s 50 day simple moving average is $35.11 and its 200-day simple moving average is $42.75.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AMPH shares. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Finally, Piper Sandler downgraded Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $66.00 to $36.00 in a research note on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $50.33.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now owns 118,469 shares of the company’s stock, valued at $5,262,392.98. This trade represents a 5.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the sale, the director now directly owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.